Skip to main content
Contact Us
Subscribe
E-Edition
63°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Today 6:45 EDT
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
March 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
March 21, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
March 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
March 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
March 13, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
March 11, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
March 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
February 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
February 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health to Acquire Elanco’s Aqua Business
February 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
ELAN
MRK
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
February 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
January 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
January 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2024 Dividend
January 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
January 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
January 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
January 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
HARP
MRK
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
January 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides U.S. Regulatory Update on Gefapixant
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
December 19, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
December 18, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
December 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
December 14, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
MRNA
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.